MorphoSys

Discussion in 'Biotech Startups' started by anonymous, Feb 8, 2020 at 12:58 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Thoughts here? Definitely doesn’t feel like a startup. Haven’t been impressed with folks and hear offers aren’t very strong. Drug looks good, pipeline so-so. Would you go?
     

  2. anonymous

    anonymous Guest

    Depends personally on your own situation. Can you take a risk? Are you excited to help build something? Is that what you really want to do? Its a job that should fit your expectations and personal goals. Its just selling drugs, its not rocket science. All these start ups are looking for diverse talent of people. Meaning different skills sets, for what? You are launching drugs. If you are strong doing that, that is what should be the focus.
    Nutty how all these companies are doing panel interviews on past achievements. Your body of work and references from former mgmt and colleagues should be enough along with how you want to build something new. Frankly all this crazy interviewing going on today is a complete waste of money and time. Fluff will always present fluff. Work horses will be just that. Fake work will show.
     
  3. anonymous

    anonymous Guest

    What kind of offers did everybody get?
     
  4. anonymous

    anonymous Guest

    Not everyone is on same timeline here.....
     
  5. anonymous

    anonymous Guest

    Co-promoting with no stock. Pay ok. Benefits average. Good if you are jobless.
     
  6. anonymous

    anonymous Guest

    Guess they did not want you bad enough if you got no stock-
    Great offer, amazing benefits, drug that could transform DLCBL landscape-
    NSD Hedge is awesome!
     
  7. anonymous

    anonymous Guest

    I call Baloney sandwich..until I see the details of the clinical trial make up and dosing scheme..
     
  8. anonymous

    anonymous Guest

    Not what I expected. I came here to be part of an organization that would treat me like an adult and use my knowledge and experience to make decisions. I was wrong with morphosys. We have a great drug but this is pure and simple primary care. Stephan and Nicole are clueless, Nicole sends out emails Applauding our number of calls thinking this is a big achievement. , bonus plan sucks as nobody is tracking to make anything at launch. We get no stock, just some vague bonus that takes 3vrs to vest. My whole team is looking even, copromoting simply sucks. A company with so much potential will start seeing massive turnover soon due to micromanagement.
     
  9. anonymous

    anonymous Guest

    I wish someone could tell me when they match the 401K .
     
  10. anonymous

    anonymous Guest

    German primary care. Like all other German companies (Bayer, BI) Morpho is hiring drones, not reps. Start goosestepping you clowns!
     
  11. anonymous

    anonymous Guest

    Stephan and Nicole, I'm going to save you from embarrassing yourself on Thursday. I've talked with multiple Morphosys Representatives and we are frustrated. This isn't what we signed up for. Both of you come from a big pharma company that is use to managing complacent managers, rule follower reps that would never leave, they are there to collect a paycheck. Here's the difference, you are now working with a group of experienced managers and top representatives that were comfortable enough in their abilities to leave the drone work of big pharma companies. We are comfortable in our knowledge and ability to take on a small biotech field and consistently be successful. We see through the B.S. of management and self justifying conference calls. We are professionals that are well respected by our customers and fellow reps in the field. We are the ones fielding the endless recruiter calls based on recommendations of our customers that feel we bring value. Honestly, we have been misled. We were told there was an equity play here, show us the paperwork. Our car allowance is paltry, with a 2 week delayed payment date. Our bonus potential is laughable, launch bonus should be attainable and reflect a big payout reflecting the uptake in the launch. The ability to blow out a plan is non existent as you only make any real money if you hit some crazy imaginary number ( I doubt most us will make our individual goal). If we had equity, that's one thing but you blow over that every time it's brought up.

    The worst is the micro-management of calls. You tell us it's what Germany wants, most of us don't buy it. That's all you know and it creates an environment of mistrust. It's your job to push back to Germany, unfortunately you are use to telling Germany what they want to hear compared to fighting for the team. We have a great drug that like any launch takes time to work through the system. This drug is being received very well by our customers and we are working very hard to work through their internal system as they dot their eyes and cross their T's to make sure they are not left holding the bag for reimbursement. Treat us like adults, enough of the B.S. You have talked Culture on many occasions. Right now our Culture is of distrust and micromanagement.
     
  12. anonymous

    anonymous Guest

    Apparently there is a huge disconnect from upper management and the field force. There are some managers who are actually advocating for their teams, others will blame their reps to gain favor with Nicole and Stephan. Those managers have created an environment of finger pointing at the field force. Many of us see the launch going great. Stephan is so busy kissing up to Germany, hes driving more metrics. Trexler is completely against stock for the field, he feels we should be fortunate to sell this drug and believes we are overpaid primadonas. The copromote just amplifies the attitude. Honestly, its going to get worse before it gets better. I have to say I've been very surprised at the disfunction here. Its simply the lack of knowledge at the executive level. So unfortunate!
     
  13. anonymous

    anonymous Guest

    Sorry you guys, you got Punked. What looked like a top tier biotech startup is just another Eurotrash trainwreck with big promises of equity. Guess what. You ain't never getting any stock.
     
  14. anonymous

    anonymous Guest

    is anyone tracking to hit goal? Heard Trexler didn't want to pay out bonus, we are lucky to sell this drug. You would be happy to have the training bonus at this point.
     
  15. anonymous

    anonymous Guest

    Why would such a growing company have its CFO leave. We just got announcement. This company has wheels coming off. The mass exodus is about to begin. Just wait by year end when nobody makes any money, reps already know there is no way to hit goal and that goal is for a 12500 bonus. How cheap!!!!
     
  16. anonymous

    anonymous Guest

    See TG Therapeutics. PDUFA date in FEB.
     
  17. anonymous

    anonymous Guest

    20 people actively interviewing, You want call average, youll get it until we get another job. Anotherfailedbiotech#
     
  18. anonymous

    anonymous Guest

    Hey stephan, your email you sent is missing one key part. You say we are vital to the success of monjuvi and we need to hit a home run. Remember any company we go to has a therapy that benefits the patients. Heres the problem with morphosys. Your not willing to put your money where your mouth is. If we are part of this company then why not an equity position that reflects that. Your entire sales team is looking and you will pay dearly. You have good reps now, wait till we leave in middle of launch. Heres the real issue, you never genuinely wanted to take care of us. We were lied to and now you think your emails and micromanagement will motivate us. Oh, we're motivated to looking for another job. #anotherfailedbiotech
     
  19. anonymous

    anonymous Guest


    Ver rr yor papers!!
     
  20. anonymous

    anonymous Guest

    Morphosys was interesting because it was a US startup with a potentially great drug. What no one knew is that it was cloaked in a big pharma blanket that aligned with Incyte for a co- promote.

    Prior to launch a survey was completed by the field and managements response was "we hear you" but they have not addressed one single issue. Motus is a joke, the insurance is now going to cost 7 thousand a year for a family of four (after deductibles) and there is no equity. We have already lost 5 reps and I'm sure more are interviewing.

    Now that we have launched the only thing that has been focused on is call activity, Veeva calls are to be entered daily. I have never seen such a focus on activity in all the years in oncology. That has all my manager has talked about, we have had text why haven't you entered calls this week, on a Wednesday morning.

    So, if you are out of work and need a gig, I would keep this as your last option. Great drug but a bad culture and a misaligned co-promote will send this ship down quickly.